Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS)
Funding Amounts: No budget limit; project period up to 5 years (R01 mechanism). Budgets must reflect actual project needs.
Summary: Supports multidisciplinary bioengineering research that integrates life and physical sciences to address biomedical problems and accelerate adoption of innovative tools, methods, or techniques.
Key Information: Clinical trials are optional; phase III trials and conventional clinical trials without a translational focus are not supported.
This opportunity from the National Institutes of Health (NIH) encourages collaborative, multidisciplinary research that applies bioengineering approaches to solve biomedical problems. The program aims to foster the development, integration, optimization, validation, and translation of innovative tools, methods, and techniques for specific research or clinical challenges in basic, translational, or clinical science.
Projects may be design-directed, developmental, discovery-driven, or hypothesis-driven, and are particularly suitable for small teams using integrative approaches. The focus is on advancing understanding and providing solutions in biological, clinical, or translational science by leveraging principles from quantitative sciences (e.g., engineering, physics, mathematics, computer science, chemistry) in combination with biomedical research.
The program will support clinical trials that test functionality or validate performance in the intended setting, but will not support conventional or late-phase (phase III) clinical trials.
All applications are due by 5:00 PM local time of the applicant organization. Letters of intent are due 30 days prior to the application due date.
Applicants requesting $500,000 or more in direct costs in any year must contact a Scientific/Research Contact at least 6 weeks before submission.
Eligible applicants include:
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as a Program Director/Principal Investigator (PD/PI) may apply.
Topic | Name | Institute | Phone | |
---|---|---|---|---|
Cancer control & population sciences | Rao Divi, Ph.D. | NCI | divir@mail.nih.gov | 240-276-6913 |
Other cancer questions | Miguel R. Ossandon, Ph.D. | NCI | ossandom@mail.nih.gov | 240-276-5714 |
Neurological disorders | Doe Kumsa, Ph.D. | NINDS | doe.kumsa@nih.gov | 301-827-5832 |
Child health & development | Toyin Ajisafe, Ph.D. | NICHD | toyin.ajisafe@nih.gov | 301-827-9242 |
Grants management (NCI) | Shane Woodward | NCI | Shane.Woodward@nih.gov | 240-276-6303 |
Grants management (NICHD) | Margaret Young | NICHD | margaret.young@nih.gov | 301-642-4552 |
Grants management (NINDS) | Chief Grants Management Officer | NINDS | ChiefGrantsManagementOfficer@ninds.nih.gov | |
General grants info | NIH Grants Info | NIH | GrantsInfo@nih.gov | 301-945-7573 |
eRA Service Desk | NIH | http://grants.nih.gov/support/ | 301-402-7469 / 866-504-9552 |